Emergent Large Vessel Occlusion Stroke During New York City's COVID-19 Outbreak: Clinical Characteristics and Paraclinical Findings.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
09 2020
Historique:
pubmed: 7 8 2020
medline: 10 9 2020
entrez: 7 8 2020
Statut: ppublish

Résumé

The 2019 novel coronavirus outbreak and its associated disease (coronavirus disease 2019 [COVID-19]) have created a worldwide pandemic. Early data suggest higher rate of ischemic stroke in severe COVID-19 infection. We evaluated whether a relationship exists between emergent large vessel occlusion (ELVO) and the ongoing COVID-19 outbreak. This is a retrospective, observational case series. Data were collected from all patients who presented with ELVO to the Mount Sinai Health System Hospitals across New York City during the peak 3 weeks of hospitalization and death from COVID-19. Patients' demographic, comorbid conditions, cardiovascular risk factors, COVID-19 disease status, and clinical presentation were extracted from the electronic medical record. Comparison was made between COVID-19 positive and negative cohorts. The incidence of ELVO stroke was compared with the pre-COVID period. Forty-five consecutive ELVO patients presented during the observation period. Fifty-three percent of patients tested positive for COVID-19. Total patients' mean (±SD) age was 66 (±17). Patients with COVID-19 were significantly younger than patients without COVID-19, 59±13 versus 74±17 (odds ratio [95% CI], 0.94 [0.81-0.98]; More than half of the ELVO stroke patients during the peak time of the New York City's COVID-19 outbreak were COVID-19 positive, and those patients with COVID-19 were younger, more likely to be male, and less likely to be White. Our findings also suggest an increase in the incidence of ELVO stroke during the peak of the COVID-19 outbreak.

Sections du résumé

BACKGROUND AND PURPOSE
The 2019 novel coronavirus outbreak and its associated disease (coronavirus disease 2019 [COVID-19]) have created a worldwide pandemic. Early data suggest higher rate of ischemic stroke in severe COVID-19 infection. We evaluated whether a relationship exists between emergent large vessel occlusion (ELVO) and the ongoing COVID-19 outbreak.
METHODS
This is a retrospective, observational case series. Data were collected from all patients who presented with ELVO to the Mount Sinai Health System Hospitals across New York City during the peak 3 weeks of hospitalization and death from COVID-19. Patients' demographic, comorbid conditions, cardiovascular risk factors, COVID-19 disease status, and clinical presentation were extracted from the electronic medical record. Comparison was made between COVID-19 positive and negative cohorts. The incidence of ELVO stroke was compared with the pre-COVID period.
RESULTS
Forty-five consecutive ELVO patients presented during the observation period. Fifty-three percent of patients tested positive for COVID-19. Total patients' mean (±SD) age was 66 (±17). Patients with COVID-19 were significantly younger than patients without COVID-19, 59±13 versus 74±17 (odds ratio [95% CI], 0.94 [0.81-0.98];
CONCLUSIONS
More than half of the ELVO stroke patients during the peak time of the New York City's COVID-19 outbreak were COVID-19 positive, and those patients with COVID-19 were younger, more likely to be male, and less likely to be White. Our findings also suggest an increase in the incidence of ELVO stroke during the peak of the COVID-19 outbreak.

Identifiants

pubmed: 32755349
doi: 10.1161/STROKEAHA.120.030397
pmc: PMC7434004
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

2656-2663

Références

J Neurol. 2004 Oct;251(10):1227-31
pubmed: 15503102
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Neurosurgery. 2019 Jul 1;85(suppl_1):S4-S8
pubmed: 31197329
Intensive Care Med. 2020 Apr;46(4):586-590
pubmed: 32125455
N Engl J Med. 2017 Feb 9;376(6):584-594
pubmed: 28177862
Circulation. 2020 May 19;141(20):1648-1655
pubmed: 32200663
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Stroke. 2008 Mar;39(3):745-52
pubmed: 18258821
Vasc Health Risk Manag. 2015 Feb 24;11:157-64
pubmed: 25750539
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Lancet. 2020 Mar 14;395(10227):846-848
pubmed: 32151325

Auteurs

Shahram Majidi (S)

Department of Neurosurgery (S.M., J.T.F., T.R.L., J.L.-R., K.A.Y., B.Y., N.D., T.J.O., T.S., R.D.L., J.M.), Icahn School of Medicine at Mount Sinai, New York, NY.

Johanna T Fifi (JT)

Department of Neurosurgery (S.M., J.T.F., T.R.L., J.L.-R., K.A.Y., B.Y., N.D., T.J.O., T.S., R.D.L., J.M.), Icahn School of Medicine at Mount Sinai, New York, NY.

Travis R Ladner (TR)

Department of Neurosurgery (S.M., J.T.F., T.R.L., J.L.-R., K.A.Y., B.Y., N.D., T.J.O., T.S., R.D.L., J.M.), Icahn School of Medicine at Mount Sinai, New York, NY.

Jacques Lara-Reyna (J)

Department of Neurosurgery (S.M., J.T.F., T.R.L., J.L.-R., K.A.Y., B.Y., N.D., T.J.O., T.S., R.D.L., J.M.), Icahn School of Medicine at Mount Sinai, New York, NY.

Kurt A Yaeger (KA)

Department of Neurosurgery (S.M., J.T.F., T.R.L., J.L.-R., K.A.Y., B.Y., N.D., T.J.O., T.S., R.D.L., J.M.), Icahn School of Medicine at Mount Sinai, New York, NY.

Benjamin Yim (B)

Department of Neurosurgery (S.M., J.T.F., T.R.L., J.L.-R., K.A.Y., B.Y., N.D., T.J.O., T.S., R.D.L., J.M.), Icahn School of Medicine at Mount Sinai, New York, NY.

Neha Dangayach (N)

Department of Neurosurgery (S.M., J.T.F., T.R.L., J.L.-R., K.A.Y., B.Y., N.D., T.J.O., T.S., R.D.L., J.M.), Icahn School of Medicine at Mount Sinai, New York, NY.

Thomas J Oxley (TJ)

Department of Neurosurgery (S.M., J.T.F., T.R.L., J.L.-R., K.A.Y., B.Y., N.D., T.J.O., T.S., R.D.L., J.M.), Icahn School of Medicine at Mount Sinai, New York, NY.

Tomoyoshi Shigematsu (T)

Department of Neurosurgery (S.M., J.T.F., T.R.L., J.L.-R., K.A.Y., B.Y., N.D., T.J.O., T.S., R.D.L., J.M.), Icahn School of Medicine at Mount Sinai, New York, NY.

Benjamin R Kummer (BR)

Department of Neurology (B.R.K., L.K.S., J.W., M.G.F., M.S.D., S.T.), Icahn School of Medicine at Mount Sinai, New York, NY.

Laura K Stein (LK)

Department of Neurology (B.R.K., L.K.S., J.W., M.G.F., M.S.D., S.T.), Icahn School of Medicine at Mount Sinai, New York, NY.

Jesse Weinberger (J)

Department of Neurology (B.R.K., L.K.S., J.W., M.G.F., M.S.D., S.T.), Icahn School of Medicine at Mount Sinai, New York, NY.

Michael G Fara (MG)

Department of Neurology (B.R.K., L.K.S., J.W., M.G.F., M.S.D., S.T.), Icahn School of Medicine at Mount Sinai, New York, NY.

Reade De Leacy (R)

Department of Neurosurgery (S.M., J.T.F., T.R.L., J.L.-R., K.A.Y., B.Y., N.D., T.J.O., T.S., R.D.L., J.M.), Icahn School of Medicine at Mount Sinai, New York, NY.

Mandip S Dhamoon (MS)

Department of Neurology (B.R.K., L.K.S., J.W., M.G.F., M.S.D., S.T.), Icahn School of Medicine at Mount Sinai, New York, NY.

Stanley Tuhrim (S)

Department of Neurology (B.R.K., L.K.S., J.W., M.G.F., M.S.D., S.T.), Icahn School of Medicine at Mount Sinai, New York, NY.

J Mocco (J)

Department of Neurosurgery (S.M., J.T.F., T.R.L., J.L.-R., K.A.Y., B.Y., N.D., T.J.O., T.S., R.D.L., J.M.), Icahn School of Medicine at Mount Sinai, New York, NY.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH